Jeena Sikho Lifecare Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 Approval of Clinical Trial of Anti-Diabetes Efficacy of SDM02 TABLETS, Shuddhi XS Syrup, Petshuddhi Churna and Shuddhi Dr. B P Care tablets.'.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts more than Nifty Microcap 250 and 4.1 pts more than its Leisure Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jeena Sikho Lifecare Limited has received approval to conduct clinical trials for the anti-diabetes efficacy of four of its products: SDM02 Tablets, Shuddhi XS Syrup, Petshuddhi Churna, and Shuddhi Dr. B P Care Tablets. The intimation was filed under Regulation 30 of SEBI (LODR) Regulations, 2015. This marks a regulatory milestone for the company's healthcare and Ayurvedic product portfolio. Clinical trial approval allows the company to formally test and validate the therapeutic claims of these products.
Positive for shareholders — successful clinical trials could open a new anti-diabetes segment, expanding the company's addressable market and supporting future revenue growth. Short-term stock reaction may be modest as clinical trials typically take time to deliver results.